多基因风险评分预测慢阻肺及相关表型
研究利用UK Biobank和SpiroMeta肺功能GWAS构建多基因风险评分,在九个多族裔队列中检验其与中重度慢阻肺的关联。
要点
- 多基因风险评分可识别中重度慢阻肺高风险个体。
- 评分与CT影像表型(肺气肿、气道壁增厚)相关。
- 评分结合临床因素可改善慢阻肺预测。
核心结论
- 多基因风险评分可识别一小部分中重度慢阻肺、吸烟相关肺气肿亚型及肺生长受限模式的高风险个体。
研究设计与样本
- 利用UK Biobank和SpiroMeta的肺功能GWAS构建多基因风险评分,在九个多族裔队列中检验其与中重度慢阻肺的关联。
- 采用逻辑回归模型校正年龄、性别、身高、吸烟包年及遗传 ancestry 主成分。
- 通过曲线下面积评估模型预测性能。
- 部分研究还分析了反映肺实质和气道病理的定量与定性CT影像表型及肺生长受限模式。
主要发现
- 多基因风险评分与CT影像表型相关,包括壁面积百分比、肺气肿定量与定性指标、局部直方图肺气肿模式及破坏性肺气肿亚型。
- 多基因风险评分与肺生长受限模式相关。
临床怎么用
- 多基因风险评分可用于识别中重度慢阻肺高风险个体,结合年龄、性别和吸烟包年可改善预测。
- 评分与肺气肿和气道病变的CT表型相关,可能辅助表型分类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genetic factors influence chronic obstructive pulmonary disease (COPD) risk, but the individual variants that have been identified have small effects. We hypothesised that a polygenic risk score using additional variants would predict COPD and associated phenotypes. METHODS: We constructed a polygenic risk score using a genome-wide association study of lung function (FEV1 and FEV1/forced vital capacity [FVC]) from the UK Biobank and SpiroMeta. We tested this polygenic risk score in nine cohorts of multiple ethnicities for an association with moderate-to-severe COPD (defined as FEV1/FVC <0·7 and FEV1 <80% of predicted). Associations were tested using logistic regression models, adjusting for age, sex, height, smoking pack-years, and principal components of genetic ancestry. We assessed predictive performance of models by area under the curve. In a subset of studies, we also studied quantitative and qualitative CT imaging phenotypes that reflect parenchymal and airway pathology, and patterns of reduced lung growth. FINDINGS: The polygenic risk score was associated with COPD in European (odds ratio [OR] per SD 1·81 [95% CI 1·74-1·88] and non-European (1·42 [1·34-1·51]) populations. Compared with the first decile, the tenth decile of the polygenic risk score was associated with COPD, with an OR of 7·99 (6·56-9·72) in European ancestry and 4·83 (3·45-6·77) in non-European ancestry cohorts. The polygenic risk score was superior to previously described genetic risk scores and, when combined with clinical risk factors (ie, age, sex, and smoking pack-years), showed improved prediction for COPD compared with a model comprising clinical risk factors alone (AUC 0·80 [0·79-0·81] vs 0·76 [0·75-0·76]). The polygenic risk score was associated with CT imaging phenotypes, including wall area percent, quantitative and qualitative measures of emphysema, local histogram emphysema patterns, and destructive emphysema subtypes. The polygenic risk score was associated with a reduced lung growth pattern. INTERPRETATION: A risk score comprised of genetic variants can identify a small subset of individuals at markedly increased risk for moderate-to-severe COPD, emphysema subtypes associated with cigarette smoking, and patterns of reduced lung growth. FUNDING: US National Institutes of Health, Wellcome Trust.
引用
- Moll M, Sakornsakolpat P, Shrine N, et al. Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts. Lancet Respir Med. 2020. PMID: 32649918. doi:10.1016/S2213-2600(20)30101-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。